Aerovate Therapeutics (AVTE) Competitors $7.72 +0.30 (+3.98%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVTE vs. PAHC, MLYS, COLL, SNDX, RCUS, ELVN, AVDL, SYRE, PHVS, and ARDXShould you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Phibro Animal Health (PAHC), Mineralys Therapeutics (MLYS), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), Enliven Therapeutics (ELVN), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), Pharvaris (PHVS), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Aerovate Therapeutics vs. Phibro Animal Health Mineralys Therapeutics Collegium Pharmaceutical Syndax Pharmaceuticals Arcus Biosciences Enliven Therapeutics Avadel Pharmaceuticals Spyre Therapeutics Pharvaris Ardelyx Phibro Animal Health (NASDAQ:PAHC) and Aerovate Therapeutics (NASDAQ:AVTE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, community ranking, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Is PAHC or AVTE more profitable? Phibro Animal Health has a net margin of 1.75% compared to Aerovate Therapeutics' net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Phibro Animal Health1.75% 25.35% 6.21% Aerovate Therapeutics N/A -90.19%-77.47% Do analysts prefer PAHC or AVTE? Phibro Animal Health currently has a consensus target price of $20.00, suggesting a potential downside of 13.98%. Aerovate Therapeutics has a consensus target price of $78.75, suggesting a potential upside of 920.74%. Given Aerovate Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aerovate Therapeutics is more favorable than Phibro Animal Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phibro Animal Health 2 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Aerovate Therapeutics 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders have more ownership in PAHC or AVTE? 99.3% of Phibro Animal Health shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media favor PAHC or AVTE? In the previous week, Phibro Animal Health had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Phibro Animal Health and 2 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 1.79 beat Phibro Animal Health's score of 1.57 indicating that Aerovate Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phibro Animal Health 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Aerovate Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable earnings & valuation, PAHC or AVTE? Phibro Animal Health has higher revenue and earnings than Aerovate Therapeutics. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPhibro Animal Health$1.19B0.79$2.42M$0.7829.81Aerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.54 Which has more risk and volatility, PAHC or AVTE? Phibro Animal Health has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Does the MarketBeat Community favor PAHC or AVTE? Phibro Animal Health received 298 more outperform votes than Aerovate Therapeutics when rated by MarketBeat users. Likewise, 59.81% of users gave Phibro Animal Health an outperform vote while only 54.29% of users gave Aerovate Therapeutics an outperform vote. CompanyUnderperformOutperformPhibro Animal HealthOutperform Votes31759.81% Underperform Votes21340.19% Aerovate TherapeuticsOutperform Votes1954.29% Underperform Votes1645.71% SummaryPhibro Animal Health beats Aerovate Therapeutics on 12 of the 16 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition Export to ExcelMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$223.62M$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-2.588.9226.7619.71Price / SalesN/A252.24389.71117.54Price / CashN/A65.8538.2534.62Price / Book1.956.466.784.50Net Income-$75.52M$143.98M$3.23B$248.18M7 Day Performance2.19%2.03%1.51%0.23%1 Month Performance-92.01%4.11%10.03%12.39%1 Year Performance-98.78%-2.87%16.65%7.07% Aerovate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate Therapeutics1.6212 of 5 stars$7.72+4.0%$78.75+920.7%-98.9%$223.62MN/A-2.5820Positive NewsGap UpHigh Trading VolumePAHCPhibro Animal Health3.5339 of 5 stars$24.50+9.0%$20.00-18.4%+26.6%$992.32M$1.11B51.041,860Positive NewsMLYSMineralys Therapeutics2.887 of 5 stars$15.01+2.5%$33.00+119.9%+29.0%$973.79MN/A-4.1228COLLCollegium Pharmaceutical4.0618 of 5 stars$29.56+2.3%$43.80+48.2%-14.6%$949.82M$631.45M12.74210Positive NewsSNDXSyndax Pharmaceuticals3.8313 of 5 stars$10.99+2.7%$35.91+226.7%-48.5%$945.66M$43.72M-3.03110Positive NewsRCUSArcus Biosciences3.55 of 5 stars$8.82+6.5%$25.67+191.2%-49.9%$933.38M$141M-2.80500Positive NewsGap DownHigh Trading VolumeELVNEnliven Therapeutics2.4841 of 5 stars$19.01+3.2%$40.33+112.2%-26.1%$932.75MN/A-10.0150Analyst RevisionAVDLAvadel Pharmaceuticals2.2233 of 5 stars$9.59+2.1%$19.43+102.6%-42.8%$926.67M$169.12M-12.1470Positive NewsSYRESpyre Therapeutics2.3332 of 5 stars$14.93+5.9%$51.17+242.7%-59.0%$899.92M$890,000.00-2.00100Positive NewsGap DownPHVSPharvaris1.2892 of 5 stars$16.81-1.1%$41.67+147.9%-20.3%$879.00MN/A-6.0030ARDXArdelyx4.4962 of 5 stars$3.53-2.5%$10.39+194.3%-48.3%$844.57M$361.71M-22.0690Insider Trade Related Companies and Tools Related Companies Phibro Animal Health Competitors Mineralys Therapeutics Competitors Collegium Pharmaceutical Competitors Syndax Pharmaceuticals Competitors Arcus Biosciences Competitors Enliven Therapeutics Competitors Avadel Pharmaceuticals Competitors Spyre Therapeutics Competitors Pharvaris Competitors Ardelyx Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVTE Stock Free AVTE Stock Alerts